NasdaqGS:GILDBiotechs
Gilead Sciences (GILD) Valuation Check After Hepcludex Wins First FDA Approval For Hepatitis Delta
The U.S. Food and Drug Administration has granted accelerated approval for Hepcludex, the first approved treatment for chronic hepatitis delta virus infection in U.S. adults, which is putting Gilead Sciences (GILD) in focus for many healthcare investors.
See our latest analysis for Gilead Sciences.
Alongside the Hepcludex approval and updates around Livdelzi and Trodelvy, Gilead’s share price has risen 10.55% year to date and its 1 year total shareholder return is 25.37%, which points to firm...